Trial Information
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma
Inclusion Criteria:
- every patient with a new diagnosis of Hodgkin or Non-Hodgkin Lymphoma (only diffuse
large B-cel lymphoma, mantle cell lymphoma, follicular lymphoma and PTLD)
Exclusion Criteria:
- patient with general contraindications for MRI (pacemaker, claustrophobia, etc.)
- patients with a type of lymphoma other than those described in the inclusion criteria
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
disease stage
Outcome Description:
Lesions are characterized as benign or malignant based on signal intensity and ADC values, enabling correct determination of tumor extent (staging).
Outcome Time Frame:
4 years
Safety Issue:
No
Principal Investigator
vincent vandecaveye, MD PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University Hospitals Leuven
Authority:
Belgium: Federal Agency for Medicinal Products and Health Products
Study ID:
S51160
NCT ID:
NCT01231269
Start Date:
November 2010
Completion Date:
July 2016
Related Keywords:
- Lymphoma:
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma (Follicular, Diffuse B-cel Lymphoma, PTLD and Mantle Cel Lymphoma)
- Hodgkin Disease
- Lymphoma
- Lymphoma, Non-Hodgkin